Overview

Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.
Phase:
Phase 2
Details
Lead Sponsor:
Canbex Therapeutics Ltd
Treatments:
3-(5-dimethylcarbamoylpent-1-enyl)-N-(2-hydroxy-1-methylethyl)benzamide